Strong new ESG rating puts Grünenthal in top 2% of the pharmaceuticals subindustry

The latest independent rating confirms Grünenthal’s improved approach to managing Environmental, Social and Governance (ESG) topics – and evaluates the company as the leader in its peer group, with a low ESG risk rating.

Stakeholders expect businesses to meet high standards for sustainability and responsibility. Investors seeking attractive long-term opportunities also pay close attention to how a company manages Environmental, Social and Governance (ESG) topics.

In this context, ESG risk ratings conducted by independent organisations offer stakeholders a trustworthy indication of a company’s impact on people and the planet. And the latest assessment by Sustainalytics, a leading ESG risk rating provider, ranks Grünenthal in the top 2% for the pharmaceuticals subindustry1 – with even stronger scores than in the previous year.